What is LCTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.25B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LCTX?

P/E (TTM) is n/a and 52-week range is $0.88 to $2.09 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LCTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LCTX?

The company profile lists revenue (TTM) near $13M, net income (TTM) near $-3.36B, EPS (TTM) near $-0.14 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Lineage Cell Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Carlsbad, California, US, 249.3M shares outstanding, ISIN US53566P1093 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Lineage Cell Therapeutics Inc

$LCTX

Health Care · Biotechnology

IR Run Scenarios

$0.99

-3.50%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 72 full-time employees. The firm programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).

Employees

Website

lineagecell.com/

IPO

1992-03-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)